Real-world data on persons living with HIV (PLWH) switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) while virologically suppressed: 96-week data from the Icona cohort

被引：0
|
作者：
Monforte, A. d'Arminio [1 ]
Tavelli, A. [1 ]
Cingolani, A. [2 ,3 ]
Taramasso, L. [4 ]
Mussini, C. [5 ]
Piconi, S. [6 ]
Calcagno, A. [7 ,8 ]
Orofino, G. [9 ]
Cicalini, S. [10 ]
Castagna, A. [11 ,12 ]
Ceccherini-Silberstein, F. [13 ]
Gori, A. [14 ,15 ]
Guaraldi, G. [5 ]
Antinori, A. [10 ]
机构：
[1] Icona Fdn, Milan, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Infect Dis Unit, Rome, Italy
[3] Univ Cattolica Sacro Cuore, Dept Safety & Bioeth, Rome, Italy
[4] Univ Genoa, Osped Policlin San Martino IRCCS, Unit Infect Dis, Genoa, Italy
[5] Univ Modena & Reggio Emilia, AOU Modena, Infect & Trop Dis Unit, Modena, Italy
[6] ASST Lecco, Infect Dis Unit, Lecce, Italy
[7] Osped Amedeo Savoia, Unit Infect Dis, Turin, Italy
[8] Univ Turin, Dept Med Sci, Turin, Italy
[9] ASL Citta Torino, Div A Infect Dis, Osped Amedeo Savoia, Turin, Italy
[10] Natl Inst Infect Dis Lazzaro Spallanzani IRCCS, Clin Dept HIV, AIDS Unit, Rome, Italy
[11] IRCCS San Raffaele Sci Inst, Infect Dis Unit, Milan, Italy
[12] Univ Vita Salute San Raffaele, Milan, Italy
[13] Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy
[14] ASST Fatebenefratelli Sacco, Unit Infect Dis 2, Milan, Italy
[15] Univ Milan, Milan, Italy
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
843
引用
收藏
页码：157 / 159
页数：3
相关论文
共 48 条
  • [11] Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV
    Rolle, Charlotte-Paige
    Nguyen, Vu
    Patel, Kiran
    Cruz, Dan
    DeJesus, Edwin
    Hinestrosa, Federico
    MEDICINE, 2021, 100 (38)
  • [12] Real-world experience using bictegravir/emtricitabine/tenofovir-alafenamide (B/F/TAF) in a Scottish HIV cohort
    Proud, E.
    Murphy, C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 46 - 47
  • [13] Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat (DRV/c) in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
    Podzamczer, D.
    Imaz, A.
    Lopez Lirola, A.
    Knobel, H.
    Masia, M.
    Berenguer, J.
    Hernandez, C.
    Lagarde, M.
    Gutierrez, A.
    Curran, A.
    Morano, L.
    Montero-Alonso, M.
    Troya, J.
    Rigo, R.
    Casadella, M.
    Navarro-Alcaraz, A.
    Rivero Roman, A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 81 - 82
  • [14] Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-infected, virologically suppressed adults
    Raffi, Francois
    Orkin, Chloe
    Clarke, Amanda
    Slama, Laurence
    Gallant, Joel
    Daar, Eric
    Yan, Mingjin
    Abram, Michael E.
    Friborg, Sandra
    Cheng, Andrew
    Rhee, Martin
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [15] Real-life data of bictegravir/ emtricitabine/tenofovir alafenamide in virologically suppressed adults living with VIH-1. 48-96 weeks results of RETROBIC study
    Troya, J.
    Mican, R.
    Pousada, G.
    Galera, C.
    Sanz, J.
    Santos, I.
    Duenas, C.
    Cabello, N.
    Martin, C.
    Galindo, M. J.
    Garcinuno, M. A.
    Hernandez, C.
    Pedrero-Tome, R.
    Ortega, D.
    Estevez, S.
    Lebon, G.
    Buzon, L.
    HIV MEDICINE, 2023, 24 : 88 - 89
  • [16] Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48-96 weeks of RETROBIC Study
    Troya, Jesus
    Pousada, Guillermo
    Mican, Rafael
    Galera, Carlos
    Sanz, Jose
    de los Santos, Ignacio
    Duenas, Carlos
    Cabello, Noemi
    Martin, Cristina
    Galindo, Maria Josefa
    Garcinuno, Maria Angeles
    Pedrero-Tome, Roberto
    Buzon, Luis
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (03) : 595 - 607
  • [17] Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort
    Lazzaro, Alessandro
    Bianchini, Diana
    Cacciola, Elio Gentilini
    Mezzaroma, Ivano
    Falciano, Mario
    Andreoni, Carolina
    Fimiani, Caterina
    Santinelli, Letizia
    Maddaloni, Luca
    Bugani, Ginevra
    Ceccarelli, Giancarlo
    Mastroianni, Claudio Maria
    d'Ettorre, Gabriella
    VIRUSES-BASEL, 2023, 15 (06):
  • [18] Changes in inflammation biomarkers after switching to TAF/FTC/BIC in experienced, virally suppressed People Living with HIV (PLHIV). Real world data
    Petrakis, V.
    Panopoulou, M.
    Rafailidis, P.
    Terzi, I.
    Ouzounakis, P.
    Papazoglou, D.
    Panagopoulos, P.
    HIV MEDICINE, 2023, 24 : 165 - 166
  • [19] Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults
    Raffi, Francois
    Orkin, Chloe
    Clarke, Amanda
    Slama, Laurence
    Gallant, Joel
    Daar, Eric
    Henry, Keith
    Santana-Bagur, Jorge
    Stein, David K.
    Bellos, Nicholaos
    Scarsella, Anthony
    Yan, Mingjin
    Abram, Michael E.
    Cheng, Andrew
    Rhee, Martin S.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 75 (02) : 226 - 231
  • [20] Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age
    Maggiolo, Franco
    Rizzardini, Giuliano
    Molina, Jean-Michel
    Pulido, Federico
    De Wit, Stephane
    Vandekerckhove, Linos
    Berenguer, Juan
    D'Antoni, Michelle L.
    Blair, Christiana
    Chuck, Susan K.
    Piontkowsky, David
    Martin, Hal
    Haubrich, Richard
    McNicholl, Ian R.
    Gallant, Joel
    HIV MEDICINE, 2023, 24 (01) : 27 - 36
12345